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Angiogenesis is essential for nutrition and growth of solid tumours
greater than 2 mm in diameter (Folkman, 1985). Unorganized
basement membrane of new capillary endothelial cells allows
intravasation of tumour cells, and a high density of microvessels in
tumours is associated with their expansion and invasiveness
(Srivastava et al, 1988; Weidner et al, 1991, 1993; Macchiarini
et al, 1992; Wakui et al, 1992). Angiogenesis consists of the
following steps: dissolution of basement membrane by proteases
released from tumour or host cells which have been activated by
tumour-derived angiogenic factors, migration and proliferation of
endothelial cells, and capillary tube formation (Folkman and
Haudenschild, 1980).
The following angiogenic factors have been identified: basic
fibroblast growth factor (FGF), vascular endothelial growth factor
(VEGF), placenta growth factor (PlGF), epidermal growth factor
(EGF), transforming growth factor (TGF)-a, TGF-b, platelet-
derived growth factor (PD-GF), platelet-derived endothelial cell
growth factor (PD-ECGF), hepatocyte growth factor (HGF),
tumour necrosis factor (TNF)-a, pleiotropin, proliferin, angio-
genin, oestradiol, interleukin (IL)-8, etc. Main angiogenic factors
induced from tumour cells are basic FGF, VEGF, PD-ECGF and
IL-8. PD-ECGF was cloned as a novel angiogenic factor (45 kDa
polypeptide) from human platelets (Ishikawa et al, 1989).
Thereafter, PD-ECGF was completely identified with thymidine
phosphorylase (TP) (Furukawa et al, 1992; Sumizawa et al, 1993).
PD-ECGF/TP does not stimulate the growth of endothelial cells
but rather chemotaxis of them, and induces angiogenesis in vivo
with the activation of TP as an enzyme (Haraguchi et al, 1994;
Miyadera et al, 1995). Among normal tissues, PD-ECGF is
expressed in lymph nodes, peripheral lymphocytes, spleen, lung,
liver, placenta (Yoshimura et al, 1990) and uterine endometrium
(Fujimoto et al, 1998a; Fujimoto et al, in press). Among solid
tumours, PD-ECGF is expressed in malignant gliomas, thyroid
tumours, cancers of the breast, oesophagus, stomach, colon,
pancreas, gall bladder, kidney, bladder, lung, uterine cervix
(Yoshimura et al, 1990), uterine endometrium (Fujimoto et al,
1998c) and ovary (Fujimoto et al, 1998b).
To know the potential of growth, invasion and metastasis of
uterine cervical cancer associated with angiogenesis, we studied
the correlation of PD-ECGF expression with patients￿ prognosis,
cellular proliferation, vascular density and venous invasion, and
the expressions of PD-ECGF and its mRNA related to histopatho-
logical types and clinical stages of uterine cervical cancers.
MATERIALS AND METHODS
Patients
Agreements for the following studies were obtained from all
patients and the Research Committee for Human Subjects, Gifu
University School of Medicine. One hundred and forty patients
ranging from 36 to 81 years of age underwent hysterectomy for
uterine leiomyoma, or hysterectomy or biopsy for cervical cancer
at the Department of Obstetrics and Gynaecology, Gifu University
School of Medicine, between January 1994 and October 1997.
None of the patients had received any therapy. A part of each
uterine cervical cancer and normal cervix as controls was obtained
immediately after hysterectomy and was snap-frozen in liquid
nitrogen to determine the levels of PD-ECGF and its mRNA
expressions, and a neighbouring part of the tissues was submitted
for histopathological study. The clinical stage of uterine cervical
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Obstetrics and Gynaecology (FIGO) classification (FIGO News,
1989). Sixty-two patients underwent curative resection for uterine
cervical cancer and were observed for a 24-month survival rate.
For these patients, immunohistochemical staining for PD-ECGF,
Ki-67 and factor VIII-related antigen was carried out to analyse
PD-ECGF functions related to cellular proliferation and to
microvessel density and venous invasion.
Enzyme immunoassay for determination of human
PD-ECGF antigen
All steps were carried out at 4°C. Tissues (wet weight 10—20 mg)
were homogenized in HG buffer (5 mM tris-HCl, pH 7.4, 5 mM
sodium chloride, 1 mM calcium chloride, 2 mM EGTA, 1 mM
magnesium chloride, 2 mM dithiothreitol (DTT), 25 mg ml—1 apro-
tinin, and 25 mg ml—1 leupeptin) with a Polytron homogenizer
(Kinematics, Luzern, Switzerland). This suspension was
centrifuged in a microfuge at 12 000 r.p.m. for 3 min to obtain the
supernatant. The protein concentration of samples was measured
by the method of Bradford (1976) to standardize PD-ECGF
antigen levels.
PD-ECGF antigen levels in the sample were determined by the
sandwich enzyme immunoassay described by Nishida et al (1996).
The levels of PD-ECGF were standardized with corresponding
cellular protein concentrations.
Immunohistochemistry
For formalin-fixed paraffin-embedded tissues, 4-mm sections were
cut with a microtome and dried overnight at 37°C on a silanized
slide (Dako, Carpinteria, USA). Samples were deparaffinized in
xylene at room temperature for 80 min and washed with a graded
ethanol/water mixture and then with distilled water. The samples
for PD-ECGF were soaked in phosphate-buffered saline (PBS),
those for Ki-67 were soaked in a citrate buffer and then autoclaved
at 121°C for 10 min, and those for factor VIII-related antigen were
treated with 0.3 mg ml—1 trypsin in PBS at room temperature for
20 min. The protocol for a Dako LSAB2 Kit, Peroxidase (Dako)
was followed for each sample. In the described procedures, mouse
anti-human PD-ECGF antigen 654-1 [10 mg ml—1, Nippon Roche,
Kamakura, Japan (Nishida et al, 1996)], rabbit anti-human Ki-67
antigen (10 mg ml—1, Dako), and rabbit anti-factor VIII-related
antigen (Zymed, San Francisco, USA) were used at dilutions of
1:100, 1:50 and 1:2 respectively. The proliferating cell population
was evaluated using the Ki-67 index (Nakano and Oka, 1993).
Vascular density was evaluated with microvessel counting (Maeda
et al, 1996).
Reverse transcription polymerase chain reaction
(RT-PCR) to amplify PD-ECGF mRNA
Total RNA was isolated from the cells by the acid guanidium thio-
cyanate—phenol—chloroform extraction method (Chomczynski and
Sacchi, 1987). Total RNA (3 mg) was reverse transcribed with
Moloney murine leukaemia virus reverse transcriptase (MMLV-
RTase, 200 units, Gibco BRL, Gaithersburg, MD, USA) in a buffer
of 20 mM tris-HCl, pH 8.4, 50 mM potassium chloride, 2.5 mM
magnesium chloride, 0.1 mg ml—1 bovine serum albumin, 10 mM
DTT and 0.5 mM deoxynucleotides to generate cDNAs using
random hexamer (50 ng, Gibco BRL) at 37°C for 60 min. The RT
reaction mixture was heated at 94°C for 5 min to inactivate
MMLV-RTase.
Five cycles of PCR for PD-ECGF mRNA, consisting of denatura-
tion for 1 min at 94°C, annealing for 1 min at 55°C, and extension for
1 min at 72°C, were carried out with reverse transcribed cDNA,
0.1 mM specific primers and Vent DNA polymerase (New England
Biolabs, Beverly, MA, USA) in a buffer of 10 mM potassium chlo-
ride, 20 mM tris-HCl, pH 8.8, 10 mM diammonium sulphate, 2 mM
magnesium sulphate, 0.1% Triton X-100 and 0.15 mM deoxynu-
cleotide phosphates using the IWAKI thermal sequencer TSR-300
(Iwaki Glass, Tokyo, Japan). Additionally, 23 cycles of PCR for PD-
ECGF and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
mRNA as an internal standard were carried out in the same manner.
The oligodeoxynucleotides of specific primers in PCR were
synthesized according to the published information on cDNA for
PD-ECGF (Hagiwara et al, 1991) and GAPDH (Arcari et al, 1984)
as follows: sense primer for PD-ECGF mRNA: 5¢-AGTCGGATG-
GCCATCAGCAT-3¢ (in exon 2); antisense primer for PD-ECGF
mRNA: 5¢-TGGAATGCTTGTCCACAAGC-3¢ (in exon 3); sense
primer for GAPDH mRNA: 5¢-TGAAGGTCGGAGTCAACG-
GATTTGGT-3¢ (in exon 2); antisense primer for GAPDH mRNA:
5¢-CATGTGGGCCATGAGGTCCACCAC-3¢ (in exon 8).
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Figure 1 Survival rate after curative resection for squamous cell carcinoma
of the uterine cervix. Prognosis of the patients was analysed with a 24-month
survival rate. High PD-ECGF, > 2500 pg mg–1 protein, n = 24; low PD-ECGF,
< 1000 pg mg–1 protein, n = 7
Figure 2 Immunohistochemical staining for PD-ECGF in uterine cervical
cancer. Positive staining is seen in the cytoplasm and nuclear compartments
of the cancer cells and in the interstitium (original magnification ´ 200)Southern blot analysis for quantities of PD-ECGF
mRNA expression
PCR products were applied to 1.2% agarose gel, and electro-
phoresis was performed at 50—100 V. PCR products were capillary
transferred to an Immobilon transfer membrane (Millipore,
Bedford, MA, USA) for 16 h. The membrane was dried at 80°C
for 30 min, and was UV irradiated to tightly fix the PCR products.
PCR products on the membrane were prehybridized in 1 M sodium
chloride, 50 mM Tris-HCl, pH 7.6, and 1% sodium dodecyl
sulphate at 42°C for 1 h, and hybridized in the same solution with
the biotinylated oligodeoxynucleotide probes synthesized from the
sequences of PD-ECGF and GAPDH cDNAs between the specific
primers at 65°C overnight. Specific bands hybridized with the
biotinylated probes were detected with Plex Luminescent Kits
(Millipore), and radiographic film was exposed on the membrane
at room temperature for 10 min. The quantification of Southern
blot was carried out with Bio Image (Millipore, Ann Arbor, MI,
USA). The intensity of specific bands was standardized with that
of GAPDH mRNA.
Statistics
Survival curves were calculated using the Kaplan—Meier method
and analysed with the log-rank test. The correlations between the
level of PD-ECGF and microvessel count, and between the level of
PD-ECGF and Ki-67 index were analysed with Spearman￿s corre-
lation coefficient. The levels of PD-ECGF and its mRNA were
measured from three parts of the same tissue in triplicate.
Statistical analysis was performed with Student￿s t-test.
Differences were considered significant when the P-value was less
than 0.05.
RESULTS
Among the 62 patients who underwent curative resection and were
observed for a 24-month survival rate, the prognosis of the 24
patients with high PD-ECGF (> 2500 pg mg—1 protein) squamous
cell carcinomas was significantly (P < 0.01) worse than that of
the seven patients with low PD-ECGF (< 1000 pg mg—1 protein)
squamous cell carcinomas (Figure 1). There was no correlation
between PD-ECGF level and the patients￿ age (data not shown).
In the corresponding 62 tumours, immunohistochemical staining
for PD-ECGF was carried out to study PD-ECGF localization in the
tumours, and strength of staining was correlated with PD-ECGF
levels measured by an enzyme immunoassay. As shown in Figure
2, PD-ECGF was distributed in the surrounding interstitium near
cancer cells and in the cytoplasm and nuclear compartments of the
cancer cells. PD-ECGF levels correlated approximately with the
strength of PD-ECGF staining.
There was a significant correlation between PD-ECGF levels
and Ki-67 indices as shown in Figure 3 (y = 23.93 + 0.005x, r =
0.57, P < 0.01), and between PD-ECGF levels and microvessel
counts as shown in Figure 4 (y = 14.84 + 0.005x, r = 0.58, P <
0.01). Venous invasion occurred significantly more (P < 0.01) in
high PD-ECGF tumours than in low PD-ECGF tumours (Figure 5).
The signal intensity curve for mRNA expression was necessary
for accurate measurement of the mRNA by RT-PCR. PCR
template was prepared from reverse transcribed total RNA
(100 mg) from normal uterine cervices as follows: 0.25´, 0.75 mg
total RNA reverse transcribed (RNA-RT); 0.5´, 1.5 mg RNA-RT;
1´, 3 mg RNA-RT; 2´, 6 mg RNA-RT; 4´, 12 mg RNA-RT; 8´,
24 mg RNA-RT; and 16´, 48 mg RNA-RT. PCR Southern blot was
carried out as described in the Materials and methods section. The
signal intensity curve for PD-ECGF mRNA levels ranging from
0.25´ to 8´ of reverse transcribed total RNA of normal uterine
cervices by RT-PCR Southern blot was linear (Figure 6).
Therefore, semiquantitative alteration of the mRNA levels was
thought to be reliable.
PD-ECGF in uterine cervical cancers 1251
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Figure 3 Correlation between PD-ECGF level and Ki-67 index
Figure 4 Correlation between PD-ECGF level and microvessel count
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PD-ECGF level (pg mg–1 protein)PD-ECGF and its mRNA had a wider range and were expressed
significantly higher (P < 0.05) in uterine cervical cancers, espe-
cially squamous cell carcinoma, than in normal uterine cervices,
regardless of clinical stage (Figures 7 and 8). Furthermore, the
levels tended to be higher in squamous cell carcinomas than in
adenocarcinomas (Figures 7 and 8).
DISCUSSION
Newly developed capillary network formation from the original
vessel is designated as neovascularization. Generally, turnover of
capillary endothelial cells is extremely slow, in the order of
months or years in physiological neovascularization, whereas the
turnover in ovary and uterine endometrium is rapidly altered along
with the ovarian cycle. The turnover with malignant transforma-
tion becomes rapid, which might contribute to the acceleration of
tumour growth (Denekamp, 1984).
Expression of tumour cell-derived angiogenic factors, basic
FGF, VEGF, PD-ECGF and IL-8, may be specific for each tumour
and be dependent on the process of tumour growth and spreading.
For example, bladder cancers express VEGF in a three-fold excess
and PD-ECGF in a 40-fold excess to the corresponding normal
tissue (O￿Brien et al, 1995). Furthermore, VEGF is dominantly
expressed in superficially invasive bladder cancer cases whereas
PD-ECGF is dominantly expressed in deeply invasive cases
(O￿Brien et al, 1995), indicating that the latter is a tumour
advancing factor which acts mainly via angiogenic activity. The
expression of basic FGF is high in uterine cervical cancers, and
increases with dedifferentiation and advancing stage (Fujimoto et
al, 1995). In contrast, the expression of VEGF is high in uterine
cervical cancers, especially adenocarcinoma, and decreases with
advancing stage (data not yet published).
Many authors have reported that a high microvessel density
correlates with poor patient prognosis in uterine cervical cancers
(Kainz et al, 1995; Rutgers et al, 1995; Wiggins et al, 1995;
Bremer et al, 1996; Dinh et al, 1996; Dellas et al, 1997; Obermair
et al, 1998). In the present study, the prognosis of the patients with
high PD-ECGF squamous cell carcinomas was worse than those
with low PD-ECGF squamous cell carcinomas, and PD-ECGF
expression correlated with Ki-67 index as an indicator of cellular
proliferation (Sawhney and Hall, 1992), microvessel density and
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Figure 5 Correlation between PD-ECGF level and venous invasion.
*P < 0.05 vs positive venous invasion
Figure 7 Levels of PD-ECGF and its mRNA in uterine cervical cancers
classified according to histological types. The levels of PD-ECGF and its
mRNA were determined by a sandwich enzyme immunoassay and RT-PCR
Southern blot analysis respectively. The mRNA level in normal uterine
cervices as controls was assigned as AU/GAPDH mRNA. Histological types
of uterine cervical cancers are according to the International Federation of
Gynaecology and Obstetrics (FIGO) classification. Each level is the mean ±
s.d. of nine determinations. K, keratinizing squamous cell carcinoma; LNK,
large-cell non-keratinizing squamous cell carcinoma; SNK, small-cell non-
keratinizing squamous cell carcinoma; AD, adenocarcinoma. *P < 0.05 vs K,
LNK, SNK and AD; **P < 0.1 vs K, LNK and SNK
Figure 6 Signal intensity curve for PD-ECGF mRNA level in a series of
reverse transcribed total RNA of normal uterine cervix by reverse
transcription polymerase chain reaction (RT-PCR) Southern blot analysis.
PCR templates were prepared from reverse transcribed total RNA (100 mg) in
normal uterine cervices as follows: 0.25 ´, 0.75 mg total RNA reverse
transcribed (RNA-RT); 0.5 ´, 1.5 mg RNA-RT; 1 ´, 3 mg RNA-RT; 2´, 6 mg
RNA-RT; 4´, 12 mg RNA-RT; 8´, 24 mg RNA-RT; and 16´, 48 mg RNA-RT.
PCR Southern blot was carried out as described in the Materials and
methods section. The levels of mRNA expression in normal uterine cervices
were assigned as arbitrary units/GAPDH mRNA (AU/GAPDH mRNA). Data
are the means ± S.D. of six determinations
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(30) (30) (30) (30) (20)vascular invasion. Therefore, PD-ECGF might contribute to the
growth of uterine cervical cancers via angiogenesis related to
vascular spreading. Furthermore, the levels of PD-ECGF and its
mRNA were higher in uterine cervical cancers, especially squa-
mous cell carcinomas, than in normal uterine cervices, however
they did not alter with different histopathological types among
squamous cell carcinomas or with advancing stage. In immuno-
histochemical studies, stronger staining of PD-ECGF is found in
squamous cell carcinomas than in adenocarcinomas of the uterine
cervix (Tokumo et al, 1998). The tumour cell-derived angiogenic
factors basic FGF, VEGF and PD-ECGF may be uniquely
expressed and dependent on the process of tumour growth and
spreading, and PD-ECGF in uterine cervical cancers might play a
role of basic angiogenesis in all processes of advancing of uterine
cervical cancers. This indicates that 5¢-deoxy-5-fluorouridine
might be highly effective on squamous cell carcinomas of the
uterine cervix, which possesses a high activity of thymidine phos-
phorylase to convert 5¢-deoxy-5-fluorouridine to 5-fluorouracil
(Miwa et al, 1987) regardless of the clinical stage, but related to
patients￿ prognosis, and that some angiogenic inhibitors (Ingber et
al, 1990) of new capillary formation might be effective in the inhi-
bition of tumour growth and spreading associated with angio-
genesis regardless of a direct tumoral effect on cancer cells.
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Figure 8 Levels of PD-ECGF and its mRNA in uterine cervical cancers
classified according to clinical stages. Clinical stages of uterine cervical
cancer are according to FIGO. *P < 0.05 vs I, II, and III and IV
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